ArticleBritish journal of clinical pharmacology2018
Additional evidence for a therapeutic effect of dextromethorphan/quinidine on bulbar motor function in patients with amyotrophic lateral sclerosis: A quantitative speech analysis.
Article in British journal of clinical pharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 39 citations in OpenAlex.
- Speech-based digital endpoints track ALS progression and align with standard clinical outcomes: evidence from the VRG50635 trial.Scientific reports · 2026Article
- A mechanistically informed framework of hierarchical temporal speech organization for objective differential assessment of motor speech disorders in neurodegenerative diseases.Frontiers in neuroscience · 2026Article
- Repurposing Sigma-1 Receptor-Targeting Drugs for Therapeutic Advances in Neurodegenerative Disorders.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Article
- Multimodal Technologies for Remote Assessment of Neurological and Mental Health.Journal of speech, language, and hearing research : JSLHR · 2024Review
- The relationship of rate and pause features to the communicative participation of people living with ALS.Muscle & nerve · 2024Article
- Validation of the Center for Neurologic Study Bulbar Function Scale-Chinese version in a population with amyotrophic lateral sclerosis.Orphanet journal of rare diseases · 2024Article
- Speech timing and monosyllabic diadochokinesis measures in the assessment of amyotrophic lateral sclerosis in Canadian French.International journal of speech-language pathology · 2024Article
- A novel muscle network approach for objective assessment and profiling of bulbar involvement in ALS.Frontiers in neuroscience · 2024Article
- A multimodal approach to automated hierarchical assessment of bulbar involvement in amyotrophic lateral sclerosis.Frontiers in neurology · 2024Article
- Dextromethorphan/quinidine for the treatment of bulbar impairment in amyotrophic lateral sclerosis.Annals of clinical and translational neurology · 2023Article
- Targeting Sigma Receptors for the Treatment of Neurodegenerative and Neurodevelopmental Disorders.CNS drugs · 2023Review
- Immunization with Neural-Derived Peptides in Neurodegenerative Diseases: A Narrative Review.Biomedicines · 2023Review
- Wearable device and smartphone data quantify ALS progression and may provide novel outcome measures.NPJ digital medicine · 2023Article
- The efficacy of acoustic-based articulatory phenotyping for characterizing and classifying four divergent neurodegenerative diseases using sequential motion rates.Journal of neural transmission (Vienna, Austria : 1996) · 2022Article
- Acoustic and Kinematic Assessment of Motor Speech Impairment in Patients With Suspected Four-Repeat Tauopathies.Journal of speech, language, and hearing research : JSLHR · 2022Article
- Pharmacotherapy for Amyotrophic Lateral Sclerosis: A Review of Approved and Upcoming Agents.Drugs · 2022Review
- A machine-learning based objective measure for ALS disease severity.NPJ digital medicine · 2022Article
- Evidence-Based Research Strategy of Traditional Chinese Medicine for Amyotrophic Lateral Sclerosis.Evidence-based complementary and alternative medicine : eCAM · 2021Review
- Clinical care and therapeutic trials in PLS.Amyotrophic lateral sclerosis & frontotemporal degeneration · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 7 institutions in 1 country.
Funding
Abstract
aimsA recent double-blind placebo-controlled crossover 70-day trial demonstrated that a fixed combination of dextromethorphan and quinidine (DM/Q) improves speech and swallowing function in most patients with amyotrophic lateral sclerosis. In this study, a subset of participants, many of whom did not substantially improve while on DM/Q, were re-evaluated using computer-based speech analyses and expert clinician ratings of the overall severity of speech impairment.
methodsSpeech samples were recorded from the subset of 10 patients at four visits made at approximately 30-day intervals. The recordings were analysed by automated computer-based analysis of speech pausing patterns. Severity of speech impairment was rated by three experienced speech-language pathologists using direct magnitude estimation. Scores on patient-reported and clinician-administered scales of bulbar motor involvement were obtained at each visit.
resultsThe effects of DM/Q were detected on several of the objective speech measures, including total pause duration (s) (Cohen's d = 0.73, 95% confidence interval (CI) -1.70, 0.24), pause time (%) (d = 0.77, 95% CI -1.75, 0.21), and mean speech event duration (s) (d = 0.52, 95% CI -0.44, 1.47), but not on clinician ratings of speech or the speech components of the self-report or clinician-administered scales.
conclusionsThese findings suggest that even patients with modest improvement while on DM/Q may experience quantifiable improvements in speech when assessed using sensitive and objective measures. This study provides additional evidence of the positive impact of DM/Q on one or more of the neural systems that control bulbar motor function and production of speech.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.